1179 related articles for article (PubMed ID: 29625575)
1. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
3. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
[TBL] [Abstract][Full Text] [Related]
4. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
5. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
[TBL] [Abstract][Full Text] [Related]
6. Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.
He Q; Wang HH; Cheng T; Yuan WP; Ma YP; Jiang YP; Ren ZH
Chin Med Sci J; 2017 Sep; 32(3):135-144. PubMed ID: 28956740
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
[TBL] [Abstract][Full Text] [Related]
8. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
[TBL] [Abstract][Full Text] [Related]
10. Site-Specific Genome Engineering in Human Pluripotent Stem Cells.
Merkert S; Martin U
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935
[TBL] [Abstract][Full Text] [Related]
11. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte-Like Cells Derived From Mouse Induced Pluripotent Stem Cells Produce Functional Coagulation Factor IX in a Hemophilia B Mouse Model.
Wu YM; Huang YJ; Chen P; Hsu YC; Lin SW; Lai HS; Lee HS
Cell Transplant; 2016; 25(7):1237-46. PubMed ID: 26395869
[TBL] [Abstract][Full Text] [Related]
13. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
14. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
15. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
16. Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs.
Sung JJ; Park CY; Leem JW; Cho MS; Kim DW
Exp Mol Med; 2019 Apr; 51(4):1-9. PubMed ID: 30996250
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
Huai C; Jia C; Sun R; Xu P; Min T; Wang Q; Zheng C; Chen H; Lu D
Hum Genet; 2017 Jul; 136(7):875-883. PubMed ID: 28508290
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
20. Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.
Ramaswamy S; Tonnu N; Menon T; Lewis BM; Green KT; Wampler D; Monahan PE; Verma IM
Cell Rep; 2018 May; 23(5):1565-1580. PubMed ID: 29719266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
